Lotus Pharmaceutical Dividends and Buybacks
Dividend criteria checks 2/6
Lotus Pharmaceutical is a dividend paying company with a current yield of 1.63% that is well covered by earnings.
Key information
1.6%
Dividend yield
-0.0003%
Buyback Yield
| Total Shareholder Yield | 1.6% |
| Future Dividend Yield | 2.7% |
| Dividend Growth | 52.3% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | NT$4.647 |
| Payout ratio | 28% |
Recent dividend and buyback updates
Recent updates
Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings
Dec 04
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 16Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem
Nov 14Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden
Oct 23Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next
Aug 14Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)
Jul 18Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?
Apr 24Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price
Apr 09Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals
Mar 22These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively
Apr 04Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 09Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?
Feb 11
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?
Jan 21Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?
Dec 31I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease
Dec 10Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next
Nov 19Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, 1795 has been paying a dividend for less than 10 years.
Growing Dividend: 1795's dividend payments have increased, but the company has only paid a dividend for 4 years.
Dividend Yield vs Market
| Lotus Pharmaceutical Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (1795) | 1.6% |
| Market Bottom 25% (TW) | 1.7% |
| Market Top 25% (TW) | 4.4% |
| Industry Average (Pharmaceuticals) | 2.1% |
| Analyst forecast (1795) (up to 3 years) | 2.7% |
Notable Dividend: 1795's dividend (1.63%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.71%).
High Dividend: 1795's dividend (1.63%) is low compared to the top 25% of dividend payers in the TW market (4.38%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (28.1%), 1795's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (37.5%), 1795's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 14:44 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lotus Pharmaceutical Co., Ltd. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Capital Securities Corporation |
| Jianzheng Wu | Capital Securities Corporation |
| Hsuan Chen | KGI Securities Co. Ltd. |